欢迎来到《四川大学学报(医学版)》

绵羊李斯特菌为载体的结核多阶段T细胞表位疫苗的构建及评价

Construction and Evaluation of a Tuberculosis Multistage Vaccine Candidate Based on Recombinant Listeria ivanovii

  • 摘要:
      目的  构建以绵羊李斯特菌(Listerria ivanovii,LI)为载体的表达结核分枝杆菌(Mycobacterium tuberculosis,MTB)特征性抗原蛋白的疫苗候选菌株,并评价其生物安全性和免疫效果。
      方法  将MTB早期感染、潜伏感染和复发阶段的4种抗原基因的细胞表位串联形成融合抗原基因,即多阶段结核杆菌抗原基因,命名为msv。将msv插入含有LI同源序列的打靶质粒,利用同源重组技术构建基因组整合msv抗原基因的重组LI菌株。观察重组菌株的体外生长情况,通过Western blot验证靶抗原蛋白的表达情况,测定重组菌株对C57BL/6小鼠的半数致死量(50% lethal dose,LD50),以0.1×LD50为免疫剂量,通过尾静脉接种小鼠,通过接种前及接种后1、2、3、5、7、14 d的血清谷丙转氨酶(ALT)水平、脏器载菌量和脏器病理切片评价疫苗候选株的安全性。为测定疫苗候选株的免疫效果,另取3组小鼠分别尾静脉免疫LI-msv、LI、NS,免疫后第9天制备脾悬液,流式细胞术检测分泌干扰素-γ(IFN-γ)、肿瘤坏死因子-α(TNF-α)、白细胞介素-2(IL-2)等细胞因子的CD4+ T细胞和CD8+ T细胞水平。
      结果  成功构建能表达多阶段结核杆菌抗原的疫苗候选株LI-msv。LI-msv 对C57BL/6小鼠的LD50为3.3×108 CFU/只。通过尾静脉接种小鼠后,LI-msv主要在小鼠肝脏和脾脏内短期繁殖,7 d后能被机体清除,对肝、脾的病理损伤时间短且可恢复;流式细胞术检测结果表明接种LI-msv的小鼠脾淋巴细胞分化出了特异的IFN-γ+ CD4+ T细胞和IFN-γ+ CD8+ T细胞,阳性细胞比率较相应载体对照组和生理盐水对照组高(P<0.005);特异性TNF-α+ CD4+ T细胞比率高于相应载体对照组(P<0.01)和生理盐水对照组(P<0.005),TNF-α+ CD8+ T细胞比率高于生理盐水对照组(P<0.005)。
      结论  成功构建了一株以LI为载体的表达结核杆菌多阶段抗原的疫苗候选株。该菌株具有生物安全性,且能诱导一定的特异性细胞免疫应答,有望作为结核疫苗候选株进行深入研究。

     

    Abstract:
      Objective  To construct a recombinant Listeria ivanovii (LI) strain that expressed Mycobacterium tuberculosis (MTB) specific antigen protein as a novel multistage tuberculosis (TB) vaccine candidate, and evaluate the biosafety and immunogenicity in mouse model.
      Methods  T cell epitopes of four genes related to different stages of MTB infection were fused in series to form an antigen gene, i.e. the multistage antigen gene (named msv). Then msv was inserted into the targeting plasmid that contained LI homologous sequences. Recombinant LI strain was obtained by transfecting LI with targeting plasmid and screening the recombinant LI strain that carried msv in the genome after series of homologous gene recombination processes. The growth rate of the recombinant LI strain in vitro was observed and the expression of target protein was verified by Western blot. The 50% lethal dose (LD50) of the recombinant strain to C57BL/6 mice was measured. Mice were intravenously inoculated with vaccine candidate in dose of 0.1×LD50.The serum alanine aminotransferase (ALT) levels, bacterial load in organs, and organ pathological sections before and 1, 2, 3, 5, 7, 14 d after vaccination were used to evaluate the safety of vaccine candidate strain. To analyze the immunogenicity of vaccine candidate strain, mice were intravenously inoculated with LI-msv, LI, and NS respectively. Nine days post immunization, the spleens were isolated under sterile conditions and splenocytes were collected and stimulated. Lyphocytes which secret specific cytokines, interferon (IFN)-γ, tumor necrosis factor (TNF)-α and interleukin (IL)-2 were analyzed by flow cytometry.
      Results  A recombinant strain named LI-msv which was capable of expressing the multistage TB antigen protein was successfully constructed. The LD50 value of LI-msv for C57BL/6 mice (i.v.) was 3.3×108 CFU. After intravenously immunized the mice, this strain mainly multiplied in the liver and spleen, and was cleared at 7 d post innoculation. Such infection process caused transient pathological damages of the liver and spleen. Results of flow cytometry showed specific IFN-γ+ CD4+ and IFN-γ+ CD8+ T lymphocytes were successfully induced in LI-msv immunized mice spleen lymphocytes. The frequency of IFN-γ positive CD4+ and CD8+ T cells was significantly higher than those of vector control group and NS control group (P<0.005). Additionally, the frequency of specific TNF-α+ CD4+ T cell in LI-msv immunized group was significantly higher than that of vector control (P<0.01) and NS control group (P<0.005), and TNF-α+ CD8+ T cell frequency obviously increased than NS control group (P<0.005).
      Conclusions  A novel multistage TB vaccine candidate expressing TB multistage antigen based on LI was successfully constructed. This vaccine candidate is safe and can induce specific cellular immune response to some extent. It is promising to be further studied as a candidate vaccine against tuberculosis.

     

/

返回文章
返回